Immune-Enriched Phenotype Linked to Improved TNBC Survival After AC
Improvements likely due to underlying genomic instability, increased sensitivity to DNA-damaging chemotherapy.
Diagnosis & Disease Information
Nivolumab-Abemaciclib-Endocrine Therapy Trial Stopped Due to Toxicity
Although the combination was deemed active in HR-positive, HER2-negative disease, findings don’t support further research.
Preoperative Pembrolizumab Plus Radiotherapy Found Active in TNBC
Combining neoadjuvant pembrolizumab with radiotherapy prior to standard of care chemotherapy may increase pathologic complete responses rates in TNBC.
Oncolytic Virus Primes an Immune Response in Breast Cancer
The oncolytic virus pelareorep may mediate priming of an adaptive immune response in women with early breast cancer.
Promising Outcomes With Lenvatinib Plus Pembrolizumab in Advanced TNBC
The majority of responses seen were ongoing at data cutoff.
No Benefit to Single-Agent Pembrolizumab in Some With mTNBC Metastasized to Liver or Lung
Women with lung, liver metastases and high PD-L1 expression saw a survival benefit.
Tool Estimates Risk of Distant Recurrence, Chemotherapy Benefit in Breast Cancer
A new online tool called RSClin was shown to estimate risk of distant recurrence and adjuvant chemotherapy benefit for patients with early breast cancer.
Salvage Neoadjuvant Chemo Induces “Very Low” Pathologic Complete Response Rate
The pathologic complete response rate was low following salvage neoadjuvant chemotherapy for patients with neoadjuvant endocrine therapy resistant disease.
Adjuvant Endocrine Therapy Alone Judged Suitable for Certain Breast Cancer Patients
Certain patients with luminal early breast cancer and up to 3 involved lymph nodes can be treated with adjuvant endocrine therapy alone.
Oral Chemo Combo Delays Disease Progression in Metastatic Breast Cancer
An oral chemotherapy combination delayed disease progression in patients with metastatic breast cancer, but came with added toxicity and unknown survival benefit.
- Loading...
Loading...
Next post in SABCS 2020
Loading... 
Loading...